<DOC>
	<DOCNO>NCT02838797</DOCNO>
	<brief_summary>This study determine safety tolerability new medicine ( RQ10 ) gastrointestinal symptom Parkinson 's disease . The investigator also begin look effect medicine gastrointestinal problem . The result determine future study appropriate . In study , RQ10 compare placebo ( look-alike inactive substance ) . Participation include multiple office visit . Approximately 48 people participate .</brief_summary>
	<brief_title>RQ-00000010 Gastroparesis Constipation Parkinson 's Disease</brief_title>
	<detailed_description>This phase Ib study primary objective determine safety tolerability well pharmacokinetics single ascend dos ( SAD ) multiple ascend dos ( MAD ) RQ10 Parkinson 's disease patient . A secondary objective ass impact single dos RQ10 gastric empty Parkinson 's Disease patient well effect RQ10 gastroparesis symptom . The expected result exploratory phase Ib study allow decide whether proceed development RQ10 Parkinson 's Disease patient ( `` go-no go '' ) help design formal phase IIa `` proof concept '' study inform repeat-dose selection possible effect size Parkinson 's Disease patient .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>For Single Ascending Dose Multiple Ascending Dose study : Idiopathic Parkinson 's Disease ( UK Brain Bank Criteria ) , Hoehn &amp; Yahr stag 13 , participant may oral levodopa , dopamine agonist , monoamine oxidaseB inhibitor , catecholOmethyltransferase inhibitor , amantadine , dose must remain stable 28 day prior enrollment anticipate remain stable throughout study , participant may deep brain stimulation ( though stimulator setting must expect remain constant throughout study ) ablative surgery Parkinson 's Disease . Additional Inclusion criterion Multiple Ascending Dose study : Must symptom suggestive current gastroparesis constipation show one following : 1 . Need regular use prokinetics , laxative , stool softener kind , 2 . A total score 2 high Gastroparesis Cardinal Symptoms Index ( total score equal average score 3 subscales ) , 3 . A score 5 high gastroparesis subscale 5 high constipation subscale Gastrointestinal Symptoms Neurodegenerative Disease Scale . Dementia ( Mini Mental Status Exam &lt; 25 ) , active psychosis , severe depression ( score 4 question 1.3 Movement Disorder SocietyUnited Parkinson Disease Rating Scale ) , active suicidality measure severe suicide ideation score 4 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) , patient answer `` Yes '' 5 CSSRS Suicidal Behavior Items attempt act perform within 1 year screening , patient , opinion investigator , present risk suicide , chronic gastrointestinal disease except gastroesophageal reflux disease , history gastrointestinal surgery might impact drug absorption ( e.g . gastrectomy ) , use apomorphine , anticholinergic , carbidopa/levodopa intestinal gel Parkinson 's Disease , female participant pregnant lactating , male female participant childbearing age willing , whose partner willing , use contraception study , diabetes , symptomatic anemia , abnormal liver kidney function , cardiac arrhythmia ( past present ) abnormal QT interval entrance electrocardiogram , positive drug screen screen visit , allergy spirulina , egg , milk , wheat , pulmonary dysfunction ( e.g . Chronic Obstructive Pulmonary Disease ) , small bowel malabsorption , use medication affect gastric emptying ( macrolides , metoclopramide , domperidone , opiates , anticholinergic ) within 3 day visit 2 3 , prisoner , individual limit English proficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Gastroparesis</keyword>
	<keyword>Constipation</keyword>
	<keyword>Prokinetic</keyword>
	<keyword>5-HT4-receptor partial agonist</keyword>
</DOC>